SCHEMBL30349367

SCHEMBL30349367

CN1CCC(Nc2ncc3c(-c4ccc5ncccc5c4)c[nH]c3n2)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 6/20 0.65
▸ CLK2 P49760 2/20 0.65
▸ CLK3 P49761 2/20 0.65
▸ DYRK1B Q9Y463 3/20 0.60
▸ RET P07949 1/20 0.55
▸ FLT3 P36888 1/20 0.49
▸ CDC7 O00311 4/20 0.47
▸ DBF4 Q9UBU7 1/20 0.47
▸ CLK1 P49759 1/20 0.44
▸ CLK4 Q9HAZ1 1/20 0.44
▸ BRD4 O60885 1/20 0.43
▸ MAPK8 P45983 3/20 0.42
▸ MAPK9 P45984 2/20 0.42
▸ MAPK10 P53779 1/20 0.42
▸ EIF2AK4 Q9P2K8 1/20 0.42
▸ LCK P06239 1/20 0.42
▸ KDR P35968 1/20 0.42
▸ MAPK14 Q16539 1/20 0.42
▸ IKBKB O14920 1/20 0.41
▸ MAPK7 Q13164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25158769 1.00 DYRK1A (0.65) DYRK1ACLK2CLK3DYRK1BRET
SCHEMBL25201523 0.89 DYRK1A (0.55) DYRK1ACLK2CLK3DYRK1BRET
SCHEMBL30349412 0.89 DYRK1A (0.55) DYRK1ACLK2CLK3DYRK1BRET
SCHEMBL25158041 0.89 DYRK1A (0.55) DYRK1ACLK2CLK3DYRK1BRET
SCHEMBL25157324 0.88 DYRK1A (0.54) DYRK1ACLK2CLK3DYRK1BRET
SCHEMBL30346585 0.87 DYRK1A (0.49) DYRK1ACLK2CLK3DYRK1BRET
SCHEMBL25211955 0.87 DYRK1A (0.49) DYRK1ACLK2CLK3DYRK1BRET
SCHEMBL25157453 0.87 DYRK1A (0.55) DYRK1ACLK2CLK3DYRK1BRET
SCHEMBL25157421 0.87 DYRK1A (0.53) DYRK1ACLK2CLK3DYRK1BRET
SCHEMBL30349016 0.87 DYRK1A (0.55) DYRK1ACLK2CLK3DYRK1BRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US claimed
EP-4415818-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BioSplice Therapeutics, Inc. (US) 2024-08-21 — — EP disclosed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 DYRK1A 1/4885CLK2 466/4885CLK3 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback